近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
30．C. Zhou, Y. L. Wu, G. Chen, J. F. Feng, X. Q. Liu, C. L. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang：Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol 2011; Vol 29:7520(Poster) 31. Yi-long Wu, Caicun Zhou, Li Zhang, Reury-Perng Perng, Tony Mok: Efficacy of erlotinib across clinical subgroups in Chinese patients and a broader Asian subpopulation with advanced non-small-cell lung cancer (NSCLC): sub-analysis of the TRUST study. Journal of Thoracic Oncology 2011; (ab P3.102) (Poster) 32．C. Xue, J. J. Pan, X. Song, Y. Zhang, Q. Yu, S. Lin, J. Wu, Y. Zhao, W. Jiang, L. Zhang: Phase II study of combination of sorafenib with cisplatin and 5-fluorouracil as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2012;Vol 30:5538 (Poster) 33. Li Zhang, Meiqi Shi, Cheng Huang, Xiao-Qing Liu, Jian ping Xiong, Gongyan Chen, Wei Liu, Wenchao Liu, Yiping Zhang, Kai Li: A phase II, multi-center, Placebo controlled trial of apatinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after 2 previous treatment regimens.Proc Am Soc Clin Oncol 2012;Vol 30:7548 (Poster) 34. Tony Mok, Yi-long Wu, Sumitra Thongprasert, Chong-Jen Yu,Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Kate Jin, Matt Truman, Jin Soo Lee: A randomized placebo-controlled phase 3 study of intercalated erlotinib with gemcitabine/platinum in 1st-line advanced non-small-cell lung cancer (NSCLC): FASTACT-2. Proc Am Soc Clin Oncol 2012; Vol 30:7519 (Poster Discussion) 35. Caicun Zhou, Yi-long Wu, Xiaoqing Liu, Changli Wang, Gongyan Chen, Jifeng Feng, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chenghong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiyuyi Zhi, Yiping Zhang, Qingyu Xiu: Overall survival (OS) results from OPTIMAL, a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012; Vol 30:7520 (Poster Discussion) 36. Liping Zhao, Wanli Liu, Chong Zhao, Xiang Guo, Yan Huang, Fei Xu, Zhihuang Hu, Zhiqiang Wang, Hongyun Zhao,Li Zhang: Pharmacokinetic and pharmacodynamic analysis of fluorouracil in nasopharyngeal cancer patients. Proc Am Soc Clin Oncol 2012;Vol 30:e13021 (Publication) 37. Pierre Ferre, Zhimin Shao, Zefei Jiang, Dafang Zhong, Chen Xiaoyan, Jean-Philippe Burillon, Aurélie Petain, Grégoire Zorza, Li Zhang:Is vinorelbine pharmacokinetics modified in Asian patients when compared to Caucasian patients? Proc Am Soc Clin Oncol 2012; Vol 30:e13036 (Publication) 38. Shun Lu, Lu Li, Yi Luo, Li Zhang, Zhiwei Chen, Wu Gang, Ping Chen, Cheng Huang, Shuliang Guo Sr., Yiping Zhang, Xiangqun Song, Meijun Lv, Wei Li, Chunhong Hu, Chengping Hu: Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392). Proc Am Soc Clin Oncol 2012; Vol 30:7091(Poster) 39. Yan Sun, Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, LI Zhang, Dong Wang, Qiang Li, Shucai Zhang, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Yong Song, Ji Feng Feng, Ying Cheng, Helong Zhang, Yi Long Wu, Nong Xu, Jianying Zhou: Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. Proc Am Soc Clin Oncol 2012;Vol 30:7559 (Poster) 40. T.S.K. Mok, J.S. Lee, L. Zhang, C.-J. Yu, S. Thongprasert, G.E.I. Ladrera, V. Srimuninnimit, M.I. Truman, B. Klughammer, Y.-L. Wu: Biomarker analysis and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced Non-small cell lung cancer (NSCLC).ESMO 2012, (1226O) 41. S. Yan, S. Yuankai, Z. Li, L. Xiaoqing, C. Zhou, Z. Li, W. Dong, L. Qiang, Z. Shucai, S. Qin：Final overall survival and update biomarker analysis results from the randomized phase III ICOGEN trial. ESMO 2012, (1269P) 42. M. Xie and Z. Li:Preclinical anti-tumor activity of xl880 in nasopharyngeal carcinoma.ESMO 2012, (1027P)43. L.Zhao,W.Liu, X.Guo, C.Zhao, Y.Huang, F.Xuand L. Zhang:Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil in chinese head and neck cancer (hnc) patients.ESMO 2012, (1057P) 44. L. Paz-Ares, V. Hirsh,L. Zhang, F. De Marinis, J.C-H. Yang, H. Wakelee,T. Seto, T. Schmelter, T.J. Ong, T.S.K. Mok, E.F. Smit: Monotherapy administration of sorafenib inpatients with non-small cell lung cancer:phase iii, randomized, double-blind,placebo-controlled MISSION trial.ESMO 2012, (LBA33 PR) 45. Y. Wu,Z. Li, C. Zhou, L. Shun, Y. Zhang, M. Hou, W. Liu, J. Wang,G. Chen, Y. Zhou: Multi-center observational study on the diagnosisof non-small cell lung cancer bone metastasisand the efficacyand safety of bisphosphatestreatment (C-TONG 0801).ESMO 2012,(1359P) 46. Q. Zhou, C. Zhou, G. Chen, Y. Cheng, C. Huang, L. Zhang, Y-L Wu:A phase II study of sorafenib monotherapy in thepatients with advanced or recurrentnon-small-cell lung cancer after failure ofEGFR-TKI (C-TONG0805).ESMO 2012,(1362TiP) 47. Li Zhang, Shun Lu, Ying Cheng, Zhihuang Hu, Zhiwei Chen, Gongyan Chen, Xiaoqing Liu, Jinji Yang, Li Zhang, Jia Chen, Meijuan Huang, Min Tao, Gang Cheng, Cheng Huang, Caicun Zhou, Weimin Zhang, Hong Zhao：Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). J Clin Oncol 31, 2013 (suppl; abstr 8015) (Poster Discussion) 48. Wenhua Liang, Li Zhang： Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 31, 2013 (suppl; abstr 8089) Poster 49. Yan Huang, Li Zhang, Jian-ji Pan, Guoqing Hu, Wu Gang, Jian ping Xiong, Chaosu Hu, Lizhu Lin, Hao Yu, Haoyuan Jiang：A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens. J Clin Oncol 31, 2013 (suppl; abstr 6026)
京公网安备 11010802027423号